Viridian Therapeutics’ stock up 35% after Phase III TED data release

Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials. Viridian is in the process of filing a BLA for its TED candidate elegrobart based on two positive Phase III trials. Viridian Therapeutics saw its stock value climb on the Phase III data. Image: Thomas Fuller/SOPA Images/LightRocket via Getty Images Viridian Therapeutics’ stock is up by 35% after it announced its Phase III chronic thyroid eye disease (TED) study met its primary endpoint. The REVEAL‑2 trial (NCT06625398) investigated two doses of subcutaneous elegrobart in patients with TED. The study…

Source: Clinical Trials Arena